Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Open Letter to Management

<< Previous

Bullboard Posts

Next >>

Comment by forhandlarenon Jan 03, 2022 3:12am

134 Views

Post# 34278538

RE:RE:Open Letter to Management

Theory put into practise.

The next announcement regarding a TFC-1067 deal - will that be a term sheet or the real deal? We know that the process has been communicated between the parties. Shouldn't jeopardize the business by communicate to the shareholders what to expect. In the new era the shareholders must be considered partners instead of just milk cows.

I suspect that management attention is on their exit, but that's many years away. Please understand that the other shareholders needs value along the way, that share price matter today. It's time to create some value.

Let's write a letter to shareholders!

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?